It is Awesome! I got dumps of 250-510 exam.

250-510 assessment test sample | 250-510 free exam papers | 250-510 practice exam | 250-510 exam preparation | 250-510 braindumps -

250-510 - Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA - Dump Information

Vendor : Symantec
Exam Code : 250-510
Exam Name : Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA
Questions and Answers : 196 Q & A
Updated On : February 15, 2019
PDF Download Mirror : Pass4sure 250-510 Dump
Get Full Version : Pass4sure 250-510 Full Version

Did you tried these 250-510 real question bank and study guide.

It ended up being a frail branch of expertise to devise. I required a ebook that can nation query and solution and i actually allude it. partillerocken Questions & answers are singularly in price of every final one among credit. A whole lot obliged partillerocken for giving nice end. I had endeavored the exam 250-510 exam for 3 years constantly however couldnt make it to passing score. I understood my hole in records the challenge of making a session room.

250-510 exam is not any extra hard to pass with these Q&A.

knowing thoroughly about my time constraint, started out trying to find an smooth way out earlier than the 250-510 exam. After an extended searh, discovered the question and answers via partillerocken which absolutely made my day. imparting all in all likelihood questions with their quick and pointed answers helped hold close topics in a brief time and felt glad to comfortable accurate marks within the exam. The materials are also smooth to memorise. I am inspired and satiated with my consequences.

here are hints & tricks with dumps to certify 250-510 exam with excessive scores.

that is my first time that I took this service. I sense very assured in 250-510 however. I put together my 250-510 using questions and solutions with exam simulator softare by using partillerocken team.

How many days preparation required to pass 250-510 exam?

I put together human beings for 250-510 exam problem and refer all to your web site for similarly developed making ready. that is positively the fine website that offers strong exam material. this is the fine asset I understand of, as i have been going to severa locales if no longer all, and i have presumed that partillerocken Dumps for 250-510 is truely up to the mark. a whole lot obliged partillerocken and the exam simulator.

Right place to find 250-510 dumps paper.

I knew that I had to cleared my 250-510 exam to keep my activity in current agency and it changed into no longer smoothactivity without some assist. It became just amazing for me to research a lot from partillerocken preparation % in form of 250-510 questions answers and exam simulator. Now I proud to announce that i am 250-510 certified. exceptional workpartillerocken.

I am very happy with this 250-510 study guide.

I am very satisfied right now. You need to be questioning why i am so happy, nicely the purpose is quite clean, I just got my 250-510 test outcomes and i have made it thru them quite with out difficulty. I write over right right here as it became this partillerocken that taught me for 250-510 test and that i cant skip on with out thanking it for being so beneficiant and helpful to me sooner or later of.

Surprised to see 250-510 Latest dumps!

It become superb enjoy with the partillerocken team. they guided me plenty for development. i admire their effort.

How to prepare for 250-510 exam?

I need to admit, i was at my wits stop and knew after failing the 250-510 test the primary time that i used to be by myself. till I searched the net for my test. Many web sites had the pattern help tests and a few for round $200. i found this website and it became the bottom fee around and i in reality couldnt find the money for it however bit the bullet and acquired it right here. I know I sound like a salesman for this enterprise but I can not consider that I passed my cert exam with a ninety eight!!!!!! I opened the exam best to see nearly each query on it become blanketed on this sample! You men rock massive time! in case you want me, name me for a testimonial cuz this works oldsters!

Nice to hear that Latest dumps of 250-510 exam are available.

Im very masses happy along with your test papers particularly with the solved issues. Your test papers gave me courage to seem in the 250-510 paper with self assurance. The end result is seventy seven.25%. Over again I complete heartedly thank the partillerocken employer. No other manner to pass the 250-510 exam apart from partillerocken model papers. I in my view cleared distinct test with the help of partillerocken question economic organization. I suggest it to each one. If you need to pass the 250-510 exam then take partillerocken help.

Dont waste your time on searching internet, just cross for those 250-510 Questions and solutions.

Though I even have sufficient heritage and revel in in IT, I expected the 250-510 exam to be simpler. partillerocken has stored my time and money, with out those QAs I might have failed the 250-510 exam. I got burdened for few questions, so I nearly had to guess, however this is my fault. I need to have memorized rightly and pay attention the questions better. Its true to realize that I passed the 250-510 exam.

See more Symantec dumps

ST0-118 | 251-365 | ST0-074 | ST0-057 | 250-501 | 250-307 | 250-101 | ST0-029 | 200-309 | 850-001 | 251-312 | 250-722 | 250-223 | 250-405 | ST0-155 | ST0-147 | 250-352 | ST0-47X | 250-314 | ST0-052 | 250-250 | ST0-174 | 250-421 | ST0-29B | ST0-086 | ASC-093 | 250-308 | 250-315 | 250-504 | ST0-94X | ASC-099 | 250-323 | ST0-072 | ST0-075 | ST0-130 | 250-240 | ST0-135 | 250-272 | ST0-141 | ST0-093 | ST0-079 | ST0-132 | 250-403 | ST0-12X | ASC-012 | 250-511 | 250-530 | ST0-91W | ST0-090 | ASC-091 |

Latest Exams added on partillerocken

1Y0-340 | 1Z0-324 | 1Z0-344 | 1Z0-346 | 1Z0-813 | 1Z0-900 | 1Z0-935 | 1Z0-950 | 1Z0-967 | 1Z0-973 | 1Z0-987 | A2040-404 | A2040-918 | AZ-101 | AZ-102 | AZ-200 | AZ-300 | AZ-301 | FortiSandbox | HP2-H65 | HP2-H67 | HPE0-J57 | HPE6-A47 | JN0-662 | MB6-898 | ML0-320 | NS0-159 | NS0-181 | NS0-513 | PEGACPBA73V1 | 1Z0-628 | 1Z0-934 | 1Z0-974 | 1Z0-986 | 202-450 | 500-325 | 70-537 | 70-703 | 98-383 | 9A0-411 | AZ-100 | C2010-530 | C2210-422 | C5050-380 | C9550-413 | C9560-517 | CV0-002 | DES-1721 | MB2-719 | PT0-001 | CPA-REG | CPA-AUD | AACN-CMC | AAMA-CMA | ABEM-EMC | ACF-CCP | ACNP | ACSM-GEI | AEMT | AHIMA-CCS | ANCC-CVNC | ANCC-MSN | ANP-BC | APMLE | AXELOS-MSP | BCNS-CNS | BMAT | CCI | CCN | CCP | CDCA-ADEX | CDM | CFSW | CGRN | CNSC | COMLEX-USA | CPCE | CPM | CRNE | CVPM | DAT | DHORT | CBCP | DSST-HRM | DTR | ESPA-EST | FNS | FSMC | GPTS | IBCLC | IFSEA-CFM | LCAC | LCDC | MHAP | MSNCB | NAPLEX | NBCC-NCC | NBDE-I | NBDE-II | NCCT-ICS | NCCT-TSC | NCEES-FE | NCEES-PE | NCIDQ-CID | NCMA-CMA | NCPT | NE-BC | NNAAP-NA | NRA-FPM | NREMT-NRP | NREMT-PTE | NSCA-CPT | OCS | PACE | PANRE | PCCE | PCCN | PET | RDN | TEAS-N | VACC | WHNP | WPT-R | 156-215-80 | 1D0-621 | 1Y0-402 | 1Z0-545 | 1Z0-581 | 1Z0-853 | 250-430 | 2V0-761 | 700-551 | 700-901 | 7765X | A2040-910 | A2040-921 | C2010-825 | C2070-582 | C5050-384 | CDCS-001 | CFR-210 | NBSTSA-CST | E20-575 | HCE-5420 | HP2-H62 | HPE6-A42 | HQT-4210 | IAHCSMM-CRCST | LEED-GA | MB2-877 | MBLEX | NCIDQ | VCS-316 | 156-915-80 | 1Z0-414 | 1Z0-439 | 1Z0-447 | 1Z0-968 | 300-100 | 3V0-624 | 500-301 | 500-551 | 70-745 | 70-779 | 700-020 | 700-265 | 810-440 | 98-381 | 98-382 | 9A0-410 | CAS-003 | E20-585 | HCE-5710 | HPE2-K42 | HPE2-K43 | HPE2-K44 | HPE2-T34 | MB6-896 | VCS-256 | 1V0-701 | 1Z0-932 | 201-450 | 2VB-602 | 500-651 | 500-701 | 70-705 | 7391X | 7491X | BCB-Analyst | C2090-320 | C2150-609 | IIAP-CAP | CAT-340 | CCC | CPAT | CPFA | APA-CPP | CPT | CSWIP | Firefighter | FTCE | HPE0-J78 | HPE0-S52 | HPE2-E55 | HPE2-E69 | ITEC-Massage | JN0-210 | MB6-897 | N10-007 | PCNSE | VCS-274 | VCS-275 | VCS-413 |

See more dumps on partillerocken

A2150-563 | BAS-010 | HCE-5710 | 000-654 | HP0-J64 | ISTQB-Advanced-Level-3 | NREMT-NRP | 2B0-020 | 310-230 | 000-695 | M2090-626 | NQ0-231 | LOT-849 | 3V0-624 | 000-388 | 1Z0-046 | 000-025 | HP2-B51 | HP0-J28 | BCP-811 | 190-801 | 000-387 | HP0-M55 | CAT-240 | CBEST | M2065-741 | JN0-322 | HP0-M51 | 3M0-331 | 000-417 | C2040-440 | 190-533 | DP-022W | RH-202 | C9520-923 | 1Z0-419 | 000-332 | 050-708 | HP2-B25 | 000-189 | 9A0-064 | ISTQB-Advanced-Level-2 | 642-272 | 70-545-CSharp | HP2-B54 | 920-128 | 050-688 | 1D0-525 | 000-855 | ST0-074 |

250-510 Questions and Answers

Pass4sure 250-510 dumps | 250-510 real questions | [HOSTED-SITE]

250-510 Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA

Study Guide Prepared by Symantec Dumps Experts 250-510 Dumps and Real Questions

100% Real Questions - Exam Pass Guarantee with High Marks - Just Memorize the Answers

250-510 exam Dumps Source : Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA

Test Code : 250-510
Test Name : Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA
Vendor Name : Symantec
Q&A : 196 Real Questions

it's far unbelieveable, but 250-510 actual exam questions are availabe right here.
i am one some of the high achiever inside the 250-510 exam. What a super Q&a material they supplied. within a short time I grasped the entirety on all of the applicable topics. It become genuinely tremendous! I suffered loads whilst making ready for my preceding attempt, however this time I cleared my exam very without problems without tension and concerns. its far virtually admirable learning journey for me. thank you loads for the real help.

in which can i locate observe guide for good information contemporary 250-510 examination?
Its far hard to get the test material which has all the necessary skills to required to take the 250-510 exam. I am so lucky in that manner, I used the material which has all the required information and capabilities and additionally very useful. The topics changed into a few issue comprehensible in the provided Dumps. It honestly makes the training and analyzing in every problem count number, seamless manner. I am urging my friends to go through it.

Check out these real 250-510 questions and study help.
I handed the 250-510 exam final week and virtually depended on this dump from for my steerage. That is a incredible manner to get certified as by hook or by crook the questions come from the actual pool of exam questions used by dealer. This manner, almost all questions I have been given on the exam regarded familiar, and that i knew answers to them. This is very reliable and trustworthy, particularly given their cash once more guarantee (i have a chum who by way of hook or by crook failed an Architect degree exam and got his cash decrease again, so that is for real).

it's miles brilliant great to prepare 250-510 examination with actual examination questions.
I passed every week ago my 250-510 affirmation test. Q&A and exam Simulator are exceptional item to shop for, it clear my situation matters effects in a definitely time, i used to be stun to understand how terrific they are at their administrations. Identity want an excessive amount of obliged regarding the notable item that you in reality have that aided in the association and the use of the test. That is frequently out and away the maximum wonderful thorough and well little bit of composing. Lots obliged

250-510 question bank that works!
I missed more than one questions simplest in view that I went clean and didnt bear in brain the answer given in the unit, but when you consider that I got the relaxation right, I passed and solved forty three/50 questions. So my recommendation is to study all that i am getting from Q&A - that is the whole lot I need to pass. I handed this exam because of killexams. This p.c. is one hundred% faithful, a huge part of the questions were the identical as what I were given on the 250-510 exam.

I want actual take a look at questions today's 250-510 exam.
It changed into a very brief choice to have QA as my test associate for 250-510. I couldnt manage my happiness as I began seeing the questions about screen; they have been like copied questions from dumps, so correct. This helped me to skip with 97% within sixty five mins into the exam.

Dont forget to try those dumps questions for 250-510 exam.
i have earned better markss in 250-510 certification with the assist of pretty low-priced merchandise. I got 250-510 exam engine to take away hard concepts of this certification. I had bought 250-510 exam braindump to have brilliant grades within the certification. It become top decision because those products are designed in line with my brain-set. It helped me to get read in fifteen days and after this short time I had scored exact with the assist of these realistic merchandise consequently im writing to say way to all of you for your exquisite offerings.

Do a quick and smart pass, prepare those 250-510 Questions and answers.
After 2 instances taking my exam and failed, I heard approximately guarantee. Then i bought 250-510 Questions solutions. on line trying out Engine helped me to training to resolve query in time. I simulated this check for normally and this help me to hold recognition on questions at exam day.Now i am an IT certified! thanks!

Need updated brain dumps for 250-510 exam? Here it is.
Attempted masses to clear my 250-510 exam taking assist from the books. However the hard motives and toughinstance made things worse and that i skipped the check two instances. Ultimately, my fine pal recommended me the question& answer via way of And consider me, it labored so nicely! The exceptional contents were awesome to undergo and apprehend the subjects. I must with out issues cram it too and answered the questions in barely a hundred and 80 minutes time. Felt elated to skip well. Thank you, dumps. Way to my lovely friend too.

proper area to discover 250-510 dumps paper.
I was so much dissatisfied in the ones days due to the truth I didnt any time to prepare for 250-510 exam prep due tomy some each day routine art work I should spend maximum time at the way, a protracted distance from my domestic to my work location. I used to be a lot concerned approximately 250-510 exam, due to the reality time is so near, then in the destiny my pal advised about, that changed into the flip to my lifestyles, the solution of my all troubles. I may want to do my 250-510 exam prep on the way with out problems by the use of my pc and is so reliable and amazing.

Symantec Administration of SymantecTM Data

When To name The Feds For trade Secret Theft Investigations | Real Questions and Pass4sure dumps

Law360 (February 5, 2019, 1:forty two PM EST) -- an organization suspects that an worker, a former worker, or a manufacturing or construction companion has stolen its constructive trade secrets. What can and may the business do?

whereas many organizations...

Symantec Endpoint Encryption: Full disk encryption product overview | Real Questions and Pass4sure dumps

here's part of a series on the good full disk encryption products and equipment available in the market. For greater, check out our FDE product roundup.

Symantec Endpoint Encryption offers full disk encryption (FDE) capabilities for the inside tough drives of pcs, laptops and servers. FDE is the means that ensures all difficult drive records is encrypted so delicate records saved thereon cannot be accessed via an attacker, as long as the computer, computer or server is powered off or (in the case of a desktop) is in a hibernate state. Symantec Endpoint Encryption additionally comprises storage encryption for removable media, comparable to USB flash drives and exterior challenging drives.

Product models

The Symantec Endpoint Encryption product became first launched in October 2014, changing the Symantec pressure Encryption product. not like another companies, Symantec makes a single edition of its Endpoint Encryption utility.

it is intended to be centrally managed by means of the Symantec Endpoint Encryption administration Server product, which should be hosted in an lively listing area.

Platform support

considering the fact that Symantec Endpoint Encryption is a new product, it is simply supported on incredibly new windows working equipment (OS) types, as follows: Microsoft windows eight.1 commercial enterprise and expert, Microsoft home windows eight enterprise and professional, Microsoft windows 7 premiere, business and expert, Microsoft windows Server 2012 Datacenter and normal, and Microsoft home windows Server 2008 commercial enterprise and standard.

Encryption and authentication support

Symantec Endpoint Encryption helps using the superior Encryption regular (AES) encryption algorithm with either 128-bit keys or 256-bit keys. AES is a robust algorithm and, when used with the 256-bit key option, offers mighty insurance policy in opposition t present and rising threats.

Being a fresh product, Symantec Endpoint Encryption has no longer yet been Federal tips Processing general (FIPS) a hundred and forty-2-certified, but the validation manner is in progress. FIPS a hundred and forty-2 certification shows that a product has been independently tested to determine if it has any giant usual complications in its cryptographic implementation. Certification does not indicate that a product is foolproof, but fairly that popular weaknesses in its cryptography don't exist.

Multifactor authentication is supported by using Symantec Endpoint Encryption, along with integration with active listing services. The FDE product can use cryptographic tokens and wise playing cards as sorts of authentication besides passwords.

Symantec Endpoint Encryption presents self-carrier password healing for clients, in addition to help desk-provided password recovery. Some companies don't permit self-carrier on account of the relative ease in compromising it via social engineering assaults. The aid desk-supplied alternative gives these corporations one other means of providing a recovery function devoid of the chance inherent in self-carrier.

one other beneficial authentication feature that Symantec Endpoint Encryption presents is mitigation of brute-drive authentication assaults, customarily involving passwords. If there are too many failed authentication attempts in a row on a tool -- with the quantity determined by means of the administrator -- the device can be configured to instantly add delays between every authentication effort, as a result slowing down an attacker. Or the equipment can be configured to lock out the user and require the consumer to use both the self-carrier password healing feature or the support desk-provided recuperation choice to regain entry to the system.


As outlined above, Symantec Endpoint Encryption is designed for centralized administration by means of the Symantec Endpoint Encryption administration Server product. This ability it's meant for commercial enterprise use and not for use by means of people or by smaller organizations that do not follow centralized administration.


Symantec sells copies of Symantec Endpoint Encryption through its website and through channel partners. As with different business FDE solutions, Symantec licenses its product via device (e.g., computing device, laptop, server).

right here is the retail pricing as of November 2014.

Symantec presents a free trial of Symantec Endpoint Encryption.


Symantec Endpoint Encryption offers FDE and detachable media encryption capabilities for more recent home windows programs, pcs, laptops and servers. It isn't a workable commercial enterprise-broad alternative for agencies operating Mac OS X desktops and laptops, neither is it proper for organizations operating older types of windows on computers, laptops and servers.

Symantec Endpoint Encryption’s authentication, encryption and centralized administration capabilities are on par with competing commercial items. since the product has its own committed administration server, it doesn't matter when it comes to integration no matter if the commercial enterprise adopting it already has Symantec items installed. In different words, there is not any potential for existing Symantec purchasers as adversarial to customers of different carriers.

Symantec warns of China-based mostly espionage campaign focused on satellites | Real Questions and Pass4sure dumps

A China-based mostly cyber neighborhood is accomplishing an extensive hacking crusade by focused on satellite, telecom and defense corporations in the united states and Southeast Asia, a U.S. cybersecurity enterprise warned this week.

The motive of the hacking group, called "Thrip," is likely country wide cyber espionage, safety researchers at Symantec Corp. referred to on Tuesday.

"Thrip’s assault on telecoms and satellite operators exposes the probability that the attackers might intercept or even alter communications traffic from organisations and patrons," Symantec pointed out in a press release, adding that essentially the most worrying discovery is an try to manage satellites by way of infecting linked computers with malware.


"The assault community gave the impression to be peculiarly interested in the operational side of the company, trying to find and infecting computer systems running software that monitors and controls satellites. this implies to us that Thrip’s motives go past spying and can also include disruption," Symantec wrote in a separate blog put up.

Satellites play a primary role in telecommunications, receiving and transmitting telephone and information superhighway alerts as well as mapping and geolocation data.

Symantec pointed out in Tuesday's statement that it has tracked Thrip in view that 2013 and lately observed that the cyber community seems to have "found out new equipment and thoughts used by using the community in this most recent set of attacks."

The danger of the improved hacking toolbox is extra compounded through Thrip's ability to stay well hidden.

"They operate very quietly, mixing in to networks, and are most effective found out the use of artificial intelligence that can determine and flag their movements," Symantec Chief executive Greg Clark said in a statement.

The enterprise says it found out the new assaults via its synthetic intelligence-primarily based targeted assault Analytics, which helped the researchers spot the malicious behavior that become hiding in legit IT administration equipment.

Unquestionably it is hard assignment to pick dependable certification questions/answers assets regarding review, reputation and validity since individuals get sham because of picking incorrectly benefit. ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report dissension customers come to us for the brain dumps and pass their exams joyfully and effortlessly. We never trade off on our review, reputation and quality on the grounds that killexams review, killexams reputation and killexams customer certainty is imperative to us. Uniquely we deal with review, reputation, sham report objection, trust, validity, report and scam. On the off chance that you see any false report posted by our rivals with the name killexams sham report grievance web, sham report, scam, protest or something like this, simply remember there are constantly awful individuals harming reputation of good administrations because of their advantages. There are a huge number of fulfilled clients that pass their exams utilizing brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit, our specimen questions and test brain dumps, our exam simulator and you will realize that is the best brain dumps site.


250-505 test questions | 156-708-70 cram | A2010-654 study guide | 310-231 VCE | SY0-401 questions answers | NS0-140 Practice Test | M2065-659 braindumps | M2020-745 sample test | 9A0-701 real questions | 3103 mock exam | ISEB-ITILF free pdf download | 70-505-VB study guide | 70-504-CSharp pdf download | ST0-085 brain dumps | CIA-II test prep | 000-422 questions and answers | 156-215-80 exam questions | 299-01 practice test | E20-598 dumps questions | 1Z0-986 free pdf |

Pass4sure 250-510 Dumps and Practice Tests with Real Questions Symantec Certification examine guides are setup by IT specialists. Groups of understudies have been crying that there are an exorbitant number of questions in such a critical number of preparing exams and study help, and they are as of late can not stand to deal with the expense of any more. Seeing pros work out this extensive interpretation while still affirmation that all the learning is anchored after significant research and exam.

Are you searching out Symantec 250-510 Dumps containing actual test questions and answers for the Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA Exam prep? is here to provide you one most updated and fine source of 250-510 Dumps this is We have compiled a database of 250-510 Dumps questions from actual test that allows you to put together and pass 250-510 exam on the first attempt. Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for all tests on website
PROF17 : 10% Discount Coupon for Orders greater than $69
DEAL17 : 15% Discount Coupon for Orders more than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for All Orders encourages a magnificent numerous applicants pass the 250-510 test and get certified. We have an extensive amount of successful overviews. Our 250-510 dumps are strong, sensible, updated and of genuinely best Great to beat the issues of any exam. 250-510 dumps are latest updated and surely help in passing 250-510 exam in first attempt. Latest 250-510 dumps are reachable in experimenting with whom we are holding up our dating to get most extreme material.

The exam questions for 250-510 Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA exam is basically in perspective of two plans, PDF and Practice test program. PDF document passes on the greater part of 250-510 exam questions, arrangements which makes your making arrangements less persevering. While the 250-510 Practice test program are the complimentary detail inside the exam protest. Which serves to self-review your reinforce. The assessment hardware also works your weak regions, where you need to situated more attempt with the point that you may upgrade every one among your worries. recommend you to must endeavor its free demo, you will see the characteristic UI and besides you will imagine that its simple to change the prep mode. Regardless, ensure that, the real 250-510 exam has a greater wide assortment of questions than the preliminary shape. If, you are mollified with its demo then you could buy the real 250-510 exam protest. offers you 3 months free updates of 250-510 Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA exam questions. Our grip bunch is continually reachable at returned surrender who updates the material as and while required. Huge Discount Coupons and Promo Codes are as under;
WC2017: 60% Discount Coupon for all exams on website
PROF17: 10% Discount Coupon for Orders greater than $69
DEAL17: 15% Discount Coupon for Orders greater than $99
DECSPECIAL: 10% Special Discount Coupon for All Orders


Killexams F50-521 dumps | Killexams CFA-Level-I practice questions | Killexams 000-539 brain dumps | Killexams 000-172 practice questions | Killexams HP2-E15 cheat sheets | Killexams HP0-J37 sample test | Killexams HP0-J36 bootcamp | Killexams 000-718 free pdf | Killexams HP0-J38 braindumps | Killexams M2180-651 dump | Killexams 000-027 pdf download | Killexams HP0-D05 exam questions | Killexams TB0-106 Practice test | Killexams HP2-K23 exam prep | Killexams HP2-B109 questions answers | Killexams HP0-M39 free pdf download | Killexams VCS-254 practice exam | Killexams 1Z0-574 cram | Killexams 1Z0-584 real questions | Killexams EE0-513 study guide |


View Complete list of Brain dumps

Killexams 1Y0-456 practice exam | Killexams HP0-Y20 brain dumps | Killexams HDPCD braindumps | Killexams MB5-625 bootcamp | Killexams VCP-511 dump | Killexams M2110-233 study guide | Killexams 500-801 mock exam | Killexams VCS-318 free pdf | Killexams 1Y0-327 practice questions | Killexams 922-102 brain dumps | Killexams 920-807 test questions | Killexams JN0-310 real questions | Killexams HP2-B76 study guide | Killexams NSE8 real questions | Killexams 000-256 real questions | Killexams P2080-088 practice test | Killexams 000-M72 questions and answers | Killexams 500-452 braindumps | Killexams 000-042 dumps | Killexams HP0-M48 practice questions |

Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA

Pass 4 sure 250-510 dumps | 250-510 real questions | [HOSTED-SITE]

Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination | real questions and Pass4sure dumps

A leak in the dike

Everyone knows how mosquitos can wreck an end-of-summer picnic. But in some climates, these pesky intruders persist and carry a variety of detrimental diseases—some with no preventative vaccines or targeted therapies. One such passenger is dengue virus (DENV), which infects up to 400 million people each year and comes in several serotypes (1 to 4) and disease presentations—from mild infection to severe disease and sometimes death. But to treat or prevent dengue requires that we have a more complete picture of the disease pathology. Now, Modhiran et al. and Beatty et al. describe the results of in vitro and in vivo experiments that point to circulating dengue virus non-structural protein 1 (NS1) and the innate immune Toll-like receptor 4 (TLR4) as a focus for basic scientists as well as vaccine and drug developers.

DENV infection protects a patient from future reinfection with the same DENV serotype as well as producing temporary immune protection from severe dengue disease caused by a different DENV serotype. But unlike diamonds, this immune protection doesn’t last forever, and when the protected period passes, the patient becomes at increased risk of enhanced infection and progression to severe disease if he or she is infected with a second DENV serotype. This severe form of dengue infection is believed to result from immunopathogenic processes that induce cytokine storm and cause vascular leakage that leads to shock. Until now, no dengue viral proteins have been linked to vascular endothelium permeability (that is, vascular leakage).

Beatty et al. show that inoculation of mice with DENV NS1 protein alone induces both vascular leak and secretion of inflammatory cytokines and that administration of NS1 with a sublethal dose of DENV2 leads to lethal vascular leak syndrome. In human endothelial cell monolayers in culture, NS1 from any of the four DENV serotypes triggered endothelial barrier permeability. NS1’s pathogenic effects were blocked by NS1-immune polyclonal mouse serum or monoclonal antibodies to NS1 (in vivo and in vitro), and immunization of mice with NS1 protected against lethal DENV2 challenge.

In an independent study, Mondrian et al. explore the underlying of NS1’s effects. They show that highly purified NS1 acts as a pathogen-associated molecular pattern (PAMP) that activates mouse macrophages and human peripheral blood mononuclear cells (PBMCs) in culture via TLR4, resulting in release of inflammatory cytokines—an effect that was blocked by either a TLR4 antagonist or an anti-TLR4 antibody. Then, in an in vitro model of vascular leak, the authors found that NS1 fractured the integrity of endothelial cell monolayers through a TLR4-dependent pathway, a finding that was supported by the observation that a TLR4 antagonist quelled capillary leak in a mouse model of dengue virus infection.

Together, these new findings highlight NS1 as an instigator of dengue-associated vascular leak and thus pinpoint a potential target for dengue drugs and component for dengue vaccines.


The four dengue virus serotypes (DENV1 to DENV4) are mosquito-borne flaviviruses that cause up to ~100 million cases of dengue annually worldwide. Severe disease is thought to result from immunopathogenic processes involving serotype cross-reactive antibodies and T cells that together induce vasoactive cytokines, causing vascular leakage that leads to shock. However, no viral proteins have been directly implicated in triggering endothelial permeability, which results in vascular leakage. DENV nonstructural protein 1 (NS1) is secreted and circulates in patients’ blood during acute infection; high levels of NS1 are associated with severe disease. We show that inoculation of mice with DENV NS1 alone induces both vascular leakage and production of key inflammatory cytokines. Furthermore, simultaneous administration of NS1 with a sublethal dose of DENV2 results in a lethal vascular leak syndrome. We also demonstrate that NS1 from DENV1, DENV2, DENV3, and DENV4 triggers endothelial barrier dysfunction, causing increased permeability of human endothelial cell monolayers in vitro. These pathogenic effects of physiologically relevant amounts of NS1 in vivo and in vitro were blocked by NS1-immune polyclonal mouse serum or monoclonal antibodies to NS1, and immunization of mice with NS1 from DENV1 to DENV4 protected against lethal DENV2 challenge. These findings add an important and previously overlooked component to the causes of dengue vascular leak, identify a new potential target for dengue therapeutics, and support inclusion of NS1 in dengue vaccines.


Dengue virus (DENV) is a mosquito-borne flavivirus that is estimated to cause up to 390 million infections, 96 million cases of dengue, and ~500,000 hospitalizations annually (1). Infection with any of the four DENV serotypes (DENV1, DENV2, DENV3, and DENV4) results in a range of syndromes from inapparent infection to classic dengue fever (DF) to dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), which is characterized by vascular leakage and shock (2). Most primary DENV infections caused by any of the four serotypes are asymptomatic or lead to the self-limiting but debilitating DF; however, secondary infections with a different (heterologous) DENV serotype can lead to increased risk of severe dengue (3). Immune responses after primary DENV infection lead to protective immunity to homologous secondary infection but may either protect against or cause increased disease severity in a subsequent DENV infection with a different serotype. The latter is thought to be mediated by serotype cross-reactive T cells or antibody-dependent enhancement (ADE), whereby cross-reactive antibodies that target viral structural proteins facilitate DENV infection of Fcγ receptor–bearing cells, leading to increased viral load (4, 5). ADE and cross-reactive T cells are thought to trigger an exaggerated and skewed immune response to a previously infecting serotype, resulting in a “cytokine storm”—rapid-onset, high-level production of proinflammatory cytokines, including tumor necrosis factor–α (TNF-α) and interleukin-6 (IL-6), in the blood that leads to endothelial permeability and vascular leak (6). However, the potential role of viral proteins in mediating vascular leakage has not been demonstrated.

The DENV 10.7-kb, positive-strand RNA genome encodes a polyprotein that is posttranslationally cleaved by host and viral proteases into three structural proteins [capsid, membrane, and envelope (E)] and seven nonstructural proteins. DENV nonstructural protein 1 (NS1) is a glycosylated 48-kD protein that plays a role in both viral replication and immune evasion (7, 8). NS1 is initially translated as a monomer that is glycosylated in the endoplasmic reticulum (ER) but rapidly forms a dimer that can have four fates: association with the viral replication complex on the surface of the ER membrane, plasma membrane association via a glycophosphatidylinositol linkage on infected cells, formation of a soluble lipophilic hexamer secreted by infected cells, or binding back of the hexameric NS1 to the surface of uninfected cells via glycosaminoglycan interactions (9, 10).

Secreted soluble DENV NS1 (sNS1) is found in patient serum during acute illness and is used as a diagnostic indicator of acute DENV infection. High levels of sNS1 are associated with increased disease severity, although it is unclear whether this measure has functional significance or is just a marker of higher viremia in severe cases. sNS1 can bind host complement components directly and inhibit complement activation in solution and on the cell surface, whereas sNS1-antibody complexes can consume complement in the context of secondary human DENV infection (11–14). Although sNS1 binds to endothelial cells (12), the functional consequences of this interaction for disease pathogenesis are poorly understood. Antibodies to NS1 cross-react with platelets, endothelial cells, and thrombin and are postulated to contribute to pathogenesis (15–17). However, vaccination with NS1 or passive transfer of monoclonal antibodies to NS1 (anti-NS1 mAbs) can at least partially protect against DENV infection in mice that are injected intracranially (18–21) or intraperitoneally (22) with DENV, indicating that anti-NS1 antibodies can be protective and not pathogenic (23). NS1 is considered a promising vaccine candidate (23–26) because it is highly conserved across DENV serotypes and because it should not generate disease-enhancing antibodies.

Although the levels of sNS1 correlate with disease severity, a direct role for NS1 in triggering endothelial disruption has not yet been established; therefore, we evaluated whether NS1 compromises endothelial cell integrity and contributes to vascular leakage in vitro and in vivo, respectively, and whether the immune response to NS1 after vaccination provides protection in a lethal mouse model of DENV vascular leak syndrome.

RESULTS NS1 triggers vascular leak–mediated pathogenesis in vivo

We hypothesized that NS1 might elicit direct pathogenic effects in DENV disease and sought to test its effect in both the absence and presence of viral replication. For all experiments, we used commercially obtained recombinant NS1 produced in human embryonic kidney (HEK) 293 cells or in S2 cells. These NS1 preparations are highly purified (fig. S1A) and reported to be hexameric in structure; we confirmed that almost all the proteins are in the oligomeric form (fig. S1B). The NS1 preparation is reported to be endotoxin-free, which we confirmed using the Limulus Amebocyte Lysate assay [<0.1 EU/ml in 25 μg of NS1 from DENV1 to DENV4 NS1 (HEK 293) or DENV2 NS1 (S2)]. C57BL/6 mice deficient in the interferon-α/β receptor (Ifnar−/−) inoculated with DENV2 NS1 (10 or 20 mg/kg) in the absence of DENV infection exhibited morbidity on days 2 to 4 post-inoculation (p.i.), although they recovered by day 5 p.i. (fig. S2A). Moreover, 100% of naïve mice inoculated intravenously with DENV2 NS1 (10 mg/kg) combined with a sublethal dose [106 plaque-forming units (PFU)] of DENV2 strain D220 (hereafter referred to as DENV2) succumbed 3 to 4 days p.i., equivalent to mice receiving a lethal dose (107 PFU) of DENV2 (Fig. 1A). In contrast, mice receiving a sublethal dose of DENV2 alone or ovalbumin (OVA) (10 mg/kg) with a sublethal dose of DENV2 exhibited 100% survival and little morbidity. Mice injected with less DENV2 NS1 (5 mg/kg) combined with a sublethal dose of DENV2 all exhibited signs of disease starting day 2 p.i., and two of six mice succumbed on day 3 p.i. (Fig. 1A), suggesting a dose-dependent effect of NS1 in mediating severe dengue disease.

Fig. 1. NS1 triggers vascular leak–mediated pathogenesis in vivo.

(A) Ifnar−/− mice were infected intravenously with a lethal dose of DENV2 (107 PFU) alone (n = 7), a sublethal dose of DENV2 (106 PFU) with DENV2 NS1 [5 mg/kg (n = 6) or 10 mg/kg (n = 7)], a sublethal dose of DENV2 with OVA [5 mg/kg (n = 6) or 10 mg/kg (n = 7)] as a negative control, or DENV2 NS1 (10 mg/kg) alone (n = 7). A Kaplan-Meier survival curve is shown, with data derived from two independent experiments. Mice given NS1 (10 mg/kg) alone or OVA (5 or 10 mg/kg) + 106 PFU of DENV2 exhibited statistically significant survival using a nonparametric Mantel-Cox log-rank test (P = 0.022) compared to mice given NS1 (10 mg/kg) + 106 PFU of DENV2. (B to D) Evans blue dye was injected intravenously into mice 3 days after treatment with DENV2 NS1 (10 mg/kg) (n = 7), DENV2 NS1 (20 mg/kg) (n = 4), OVA (10 mg/kg) (n = 6), NS1 (10 mg/kg) + 106 PFU of DENV2 (n = 4), OVA + 106 PFU of DENV2 (n = 4), or 106 (n = 4) or 107 PFU of DENV2 alone (n = 7), as indicated. The dye was allowed to circulate for 1 h before mice were euthanized, tissues were harvested, and Evans blue was extracted in formamide and quantified in (B) lung, (C) liver, and (D) small intestine tissue by measuring absorbance at OD610. In all tissues, the mice given NS1 (20 mg/kg) or NS1 (10 mg/kg) alone or NS1 (10 mg/kg) + 106 PFU of DENV2 had significantly higher levels of Evans blue than the OVA controls. (E) Ifnar−/− mice were administered DENV2 NS1 (10 mg/kg) or OVA (10 mg/kg) alone, NS1 or OVA (10 mg/kg) plus 106 PFU of DENV2, or 106 or 107 PFU of DENV2 alone, as indicated (n = 4 per group). Plasma was collected 3 days after treatment, and the levels of NS1 were measured by NS1-specific capture enzyme-linked immunosorbent assay (ELISA). (B to E) Data were derived from two independent experiments and were analyzed by nonparametric Mann-Whitney analysis. *P < 0.05; **P < 0.01.

We performed parallel experiments to measure vascular leakage as detected by tissue-associated Evans blue dye, which quantifies leakage out of the circulatory system when injected intravenously. We evaluated the vascular leakage on day 3 p.i. because this day was when we observed the greatest morbidity in the NS1-injected mice (fig. S2A). Mice receiving NS1 (10 mg/kg) plus a sublethal dose of DENV2 or a lethal dose of DENV2 displayed high levels of Evans blue dye in the lung, liver, spleen, and small and large intestines (Fig. 1, B to D, and fig. S2, B and C), indicating substantial vascular leakage. Mice receiving NS1 (10 or 20 mg/kg) alone contained significantly higher levels of Evans blue in all tissues than mice administered OVA as a negative control, whereas mice receiving sublethal doses of DENV2 (plus or minus OVA) had lower but measurable levels of Evans blue (Fig. 1, B to D, and fig. S2, B and C). These data demonstrate a role for NS1 alone in inducing vascular permeability in vivo.

In a separate set of mice, we evaluated the levels of circulating NS1, viremia, and selected cytokines in serum 3 days p.i., when maximum morbidity and mortality were observed, with or without NS1 or OVA as above. Injection of NS1 (10 mg/kg) alone resulted in ~1 μg/ml circulating NS1 in serum at day 3 p.i., only slightly higher than levels in mice infected with a lethal dose of DENV2 (Fig. 1E). Mice infected with a sublethal dose of DENV2 alone or combined with OVA (10 mg/kg) had ~0.25 μg/ml circulating NS1 at day 3 p.i., whereas mice infected with a sublethal dose of DENV2 and NS1 (10 mg/kg) yielded an average of ~2 μg/ml circulating NS1 at day 3 p.i. (Fig. 1E). We also evaluated the levels of NS1 every 12 h after inoculation with NS1 (10 mg/kg) and found that they decreased from ~15 μg/ml at 12 h p.i. to ~1 μg/ml at 72 h p.i. (fig. S2D); these levels are consistent with the range seen in humans with severe dengue (~1 to >10 μg/ml) (27, 28). Viremia levels were comparable between mice receiving NS1 plus a sublethal dose of DENV2 and mice infected with a lethal dose of DENV2, and both were 10-fold greater than viremia levels in OVA plus a sublethal dose of DENV2 or a sublethal dose of DENV2 alone (fig. S2E). With respect to cytokines often associated with DHF/DSS, we found that inoculation of NS1 alone or addition of NS1 to a sublethal dose of DENV2 significantly increased levels of TNF-α and IL-6 compared to negative controls, to levels similar to those observed in mice experiencing a lethal DENV2 infection (Fig. 2, A and B). In sum, the simultaneous injection of NS1 with a sublethal dose of DENV2 resulted in a lethal infection associated with vascular leakage, and NS1 alone increased vascular leakage in vivo. Furthermore, injection of NS1 in both the presence or absence of viral infection led to increased levels of critical inflammatory cytokines.

Fig. 2. NS1 causes increased production of inflammatory cytokines in vivo in the presence or absence of DENV2.

Ifnar−/− mice were administered DENV2 NS1 (10 mg/kg) or OVA (10 mg/kg) alone, NS1 or OVA (10 mg/kg) plus 106 PFU of DENV2, or 106 or 107 PFU of DENV2 alone, as indicated (n = 4 per group). (A and B) Plasma was collected 3 days after treatment, and the levels of (A) IL-6 and (B) TNF-α were measured by ELISA. Mice given NS1 (10 mg/kg) + 106 PFU of DENV2 or NS1 (10 mg/kg) alone had significantly higher levels of both cytokines than controls receiving OVA. Data were derived from two independent experiments and were analyzed by nonparametric Mann-Whitney analysis. *P < 0.05.

NS1 causes endothelial permeability in vitro

To directly evaluate a possible role for NS1 in triggering endothelial cell dysfunction, NS1 alone was incubated with cultures of a human pulmonary microvascular endothelial cell (HPMEC) line. HPMECs were grown on Transwell permeable membranes as a model of barrier function in vitro and incubated with DENV2 NS1 (0.2 to 20 μg/ml). Endothelial cell permeability was examined by measuring the transendothelial electrical resistance (TEER) of the HPMECs at different time points after treatment with NS1. TNF-α, known to induce endothelial barrier dysfunction, was used as a positive control and resulted in decreased TEER values (Fig. 3A). DENV2 NS1 induced a significant (P < 0.0001) dose-dependent increase in endothelial permeability compared to TEER baseline values exhibited by untreated controls and treatment with control protein (20 μg/ml OVA), starting ~2 h post-treatment (hpt) and persisting for 12 to 24 hpt depending on the dose (Fig. 3A and fig. S3A). Similar results were observed in primary human umbilical vein endothelial cells (HUVEC; fig. S3B). We then tested NS1 from DENV1, DENV2, DENV3, and DENV4 at 5 or 20 μg/ml on HPMEC monolayers (Fig. 3B and fig. S3C). NS1 from all four serotypes resulted in a significant (P < 0.0001) decrease in TEER; DENV1 and DENV2 NS1 caused the greatest reduction, from 3 to 13 hpt, whereas DENV3 and DENV4 NS1 displayed similar decreases from 9 to 13 hpt. In contrast, NS1 from West Nile virus (WNV), a closely related flavivirus that causes encephalitis but no systemic vascular leak, did not trigger reduction in TEER, nor did another DENV protein (E) when administered at the same concentration (Fig. 3B and fig. S1A). Thus, NS1 alone from all four DENV serotypes, but not WNV, can directly trigger increased endothelial cell permeability.

Fig. 3. NS1 induces endothelial permeability in human pulmonary endothelial cells in vitro.

Confluent monolayers of HPMECs grown on Transwell inserts were incubated for 48 h with NS1, and TEER (ohm) was measured at indicated time points. Relative TEER (ratio of resistance values between experimental and untreated cells) was plotted. Data were normalized to inserts containing medium only. (A) Increasing concentrations of DENV2 NS1 (0.5 to 5 μg/ml) or TNF-α (1 ng/ml) were added to HPMEC monolayers, and TEER was measured at the indicated time points. (B) DENV1, DENV2, DENV3, DENV4 NS1, WNV NS1, or DENV2 E protein (5 μg/ml) was added to HPMEC monolayers, and TEER was analyzed at indicated time points. OVA (20 μg/ml) was used as a treatment control. Results are representative of three independent experiments using duplicate Transwells. Error bars indicate SEM. NS1, DENV2 NS1 (5 μg/ml).

NS1 vaccination protects against lethal DENV–induced vascular leak syndrome

Given the ability of NS1 to induce vascular leak, we hypothesized that vaccination with NS1 might constitute a strategy for protecting against severe dengue disease. To investigate whether immune responses against NS1 could prevent lethal vascular leak–associated DENV disease, we immunized Ifnar−/− mice three times intraperitoneally with 20 μg of DENV2 NS1 and several different adjuvant systems over a 6-week period (days 1, 14, and 42) and challenged the mice with a lethal DENV2 infection 2 weeks after the last immunization (day 56). Mice immunized with DENV2 NS1 and monophosphoryl lipid A (MPLA)/AddaVax were completely protected against a lethal systemic challenge (Fig. 4A) and exhibited little morbidity. Similarly, NS1/MPLA/AddaVax-immunized mice were protected against antibody-enhanced lethal challenge with DENV2 (29, 30) (Fig. 4A). None of the OVA-immunized mice survived the high-dose or ADE lethal challenge. A low-dose (105 PFU) primary homologous infection with the parental DENV2 strain PL046 provided 100% protection against lethal challenge as a positive control (Fig. 4A). Thus, immune responses to adjuvanted NS1 protein alone were sufficient to provide complete protection, comparable to immunity induced by primary DENV infection. We then immunized mice with NS1, OVA, or DENV2 PL046, subjected them to lethal DENV2 challenge, and evaluated levels of NS1 in the serum. Sera from NS1-immune mice 3 days after the challenge contained almost no detectable NS1 compared to ~0.75 μg/ml in OVA-immunized mice, whereas NS1 levels in DENV2 PL046-immune mice were reduced to a lesser degree (~0.45 μg/ml) (Fig. 4B). NS1-immune and DENV-immune mice also displayed lower viremia in serum and lower viral load in bone marrow, spleen, and small intestine after challenge compared to OVA-immunized mice (Fig. 4, C and D, and fig. S4, A and B). These data suggest that the immune response to NS1 protected against mortality by greatly reducing circulating NS1 as well as decreasing the peripheral viral load.

Fig. 4. NS1 vaccination protects against lethal DENV–induced vascular-leak syndrome.

(A) Mice were immunized intraperitoneally with 20 μg of DENV2 NS1 (n = 12) or OVA (n = 8) combined with MPLA/AddaVax adjuvants on days 0, 14, and 42 or infected with a sublethal dose (105 PFU) of DENV2 PL046 (n = 12) at day 0; on day 56, half were challenged intravenously with a lethal dose of 107 PFU of DENV2 and half with lethal antibody-enhanced DENV2 infection. A Kaplan-Meier survival curve is shown. Mice immunized with NS1 were significantly protected compared to OVA controls from both ADE (P = 0.003) and high-dose (hi-dose) (P = 0.001) lethal challenge. (B) NS1 levels in serum were measured by NS1-specific capture ELISA in NS1-immunized (n = 6) or OVA-immunized (n = 6) mice and DENV2 PL046–immune (n = 3) mice 3 days after DENV2 lethal challenge. Circulating NS1 was significantly higher in OVA-immunized compared to NS1-immunized mice after challenge; *P < 0.05; **P < 0.01. (C and D) The viral RNA copy number was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in (C) serum and (D) bone marrow 3 days post-lethal challenge. OVA-immunized mice (n = 6) had higher levels of viral RNA in both tissues compared to NS1-immunized mice (n = 6); *P < 0.05; **P < 0.01. The limit of detection is indicated by a dashed line. GAPDH, glyceraldehyde phosphate dehydrogenase. GE, genome equivalent. (E) Mice were immunized with 20 μg of NS1 from DENV1 (n = 8), DENV2 (n = 8), DENV3 (n = 5), or DENV4 (n = 5) or OVA (n = 10) with MPLA/AddaVax adjuvants as above, or 105 PFU of DENV2 PL046 (n = 10) at day 0 and then challenged intravenously on day 56 with a lethal dose of DENV2. Mice immunized with the four DENV NS1 serotypes separately were significantly protected against lethal challenge compared to OVA-immunized groups (DENV1, P = 0.002; DENV2, P = 0.008; DENV3, P = 0.004; DENV4, P = 0.014). Data were derived from three independent experiments.

Because relatively high homology exists in the amino acid sequence of NS1 within and across the four DENV serotypes (31), we examined whether immunization with NS1 could protect against a heterologous, lethal DENV infection. Mice were immunized as above with DENV1, DENV2, DENV3, or DENV4 NS1, challenged 2 weeks after the third immunization with a lethal dose of DENV2, and monitored for morbidity and mortality. As expected, DENV2 NS1 provided 100% protection against lethal homologous DENV2 challenge (Fig. 4E). Immunization with DENV1 NS1 provided 75% protection, and DENV3 or DENV4 NS1 provided 60% protection against DENV2 lethal challenge (Fig. 4E), demonstrating sufficient immune cross-reactivity to NS1 epitopes to provide partial protection across serotypes. Serum was obtained from mice 1 week after the third immunization with NS1 or OVA, which coincided with 7 weeks after DENV2 PL046 primary infection. We tested the prechallenge immune serum by ELISA for reactivity to NS1 of all four DENV serotypes (fig. S5). DENV NS1-immune sera bound strongly to NS1 from the homologous serotype and also exhibited substantial cross-reactivity to NS1 from the other three serotypes. In addition, the level of anti-NS1 antibody binding and serotype cross-reactivity was greater in NS1-immunized mice than in natural infection with the different DENV serotypes (fig. S5).

NS1-immune serum and anti-NS1 mAbs block NS1-induced vascular leak

To determine whether antibodies from NS1-immunized mice could prevent the direct effect of NS1 on endothelial permeability, we tested NS1- or OVA-immune sera from vaccinated mice on HPMEC monolayers using the TEER assay. Intact NS1-immune sera inhibited the NS1-induced decrease in TEER, whereas OVA-immune sera provided no inhibition (Fig. 5A). Heat-inactivated NS1-immune sera also inhibited the NS1-induced decrease in TEER, demonstrating that the inhibition was not dependent on complement. Sera from DENV2 PL046-immune mice partially inhibited the reduction in TEER, consistent with the lower level of anti-NS1 antibodies observed in DENV2-immune sera compared to the level in NS1-immune sera (fig. S5). To further confirm the specificity of the antibody-mediated blocking of NS1 function in vitro, a panel of anti-NS1 mAbs was evaluated, and several anti-NS1 mAbs (for example, 2B7 and 1H7.4) were shown to inhibit the NS1-induced decrease in TEER (Fig. 5B). Several other anti-NS1 mAbs (for example, 2E9.E2) did not inhibit the reduction in TEER (Fig. 5B), demonstrating that blocking certain but not all epitopes leads to the loss of NS1 disruption of endothelial integrity. As expected, mAbs directed to another DENV protein, E (for example, 3H5), did not block NS1 function in the TEER assay, nor did the anti-NS1 mAbs alone have any effect on endothelial permeability (Fig. 5B).

Fig. 5. NS1-immune serum and anti-NS1 mAbs block NS1-induced endothelial permeability in vitro.

(A) Monolayers of HPMECs grown on Transwell inserts were incubated for 48 h with both NS1 (5 μg/ml) and anti-NS1 serum (1:10 dilution), NS1 alone, or anti-NS1 serum alone, and TEER (ohm) was measured at indicated time points. OVA (5 μg/ml) was used as a protein control. Anti-OVA and anti-DENV2 PL046 sera were also included as controls. Results are representative of two independent experiments with duplicate Transwells. (B) Monolayers of HPMECs grown on Transwell inserts were incubated for 48 h with both NS1 (5 μg/ml) and NS1-specific mAbs (10 μg/ml) or either NS1 or anti-NS1 mAbs alone, and TEER (ohm) was measured at indicated time points. A mAb specific to DENV E protein (3H5) was used as an isotype control. Results are representative of three experiments, each with duplicate Transwells. Error bars indicate SEM.

To investigate the role of anti-NS1 antibodies in the protective immunity observed against NS1 toxicity in vivo, we passively transferred sera from NS1- or OVA-immunized mice (both in combination with MPLA/AddaVax) concurrently with a lethal challenge of NS1 plus a sublethal dose of DENV2. The passive transfer of 300 μl of anti–NS1-immune serum provided 100% protection from lethality, whereas mice receiving 300 μl of anti-OVA sera succumbed (Fig. 6A). Therefore, antibodies from NS1-vaccinated mice were sufficient to inhibit NS1-mediated toxicity, suggesting that anti-NS1 antibodies provide a critical component of immune protection against lethal DENV2 challenge observed in NS1-vaccinated mice.

Fig. 6. NS1-immune serum and anti-NS1 mAb block NS1-induced lethality in vivo.

(A) Pooled serum (300 μl) from NS1-immunized (n = 7), OVA-immunized (n = 7), or DENV2 PL046–immune (n = 4) mice was transferred intraperitoneally to naïve Ifnar−/− mice before intravenous injection of NS1 (10 mg/kg) + 106 PFU of DENV2. Anti-NS1 or anti-OVA serum was transferred to naïve mice before injection of OVA (10 mg/kg) + 106 PFU of DENV2 (n = 4 per group) as controls (ctrl). Mice were followed for survival for 14 days p.i. Mice administered NS1-immune serum followed by NS1 + 106 PFU of DENV2 were significantly protected (P = 0.014) against lethality compared to mice given OVA-immune serum (n = 7), using the log-rank Mantel-Cox test. Data were derived from two independent experiments. (B) Ifnar−/− mice were infected intravenously with 107 PFU of DENV2 alone (n = 3), 106 PFU of DENV2 alone (n = 3), 106 PFU of DENV2 with DENV2 NS1 (10 mg/kg), or 106 PFU of DENV2 with OVA (10 mg/kg), as indicated. Mice injected with DENV2 combined with DENV2 NS1 or OVA were concomitantly injected intraperitoneally with 200 μg of isotype control mAb or anti-NS1 mAb (1H7.4) (n = 4 for all groups). Kaplan-Meier survival curves are shown, where mice were monitored for morbidity and survival for 10 days p.i. Mice given anti-NS1 mAbs were significantly protected (P = 0.0069) against lethality compared to mice given the isotype control mAbs by log-rank Mantel-Cox test.

Finally, we tested the ability of an anti-NS1 mAb that blocked TEER function in vitro (Fig. 5B) to protect against NS1-induced toxicity in vivo. The anti-NS1 mAb was administered to mice immediately after inoculation with a sublethal viral dose plus NS1 (10 mg/kg), and the mice were monitored for morbidity and mortality for 10 days. Mice receiving the lethal virus inoculum as a positive control and the mice receiving a sublethal viral dose plus NS1 (10 mg/kg) and the isotype control succumbed to the vascular leak disease; however, the mice receiving the sublethal viral dose plus NS1 (10 mg/kg) and the anti-NS1 mAb demonstrated 100% survival (Fig. 6B). Therefore, both polyclonal and monoclonal anti-NS1 antibodies can inhibit lethal vascular permeability in vivo and can block the ability of NS1 to trigger endothelial cell dysfunction in vitro.


We have established that DENV NS1 causes vascular leak in vivo and induces increased permeability of human endothelial cells in vitro, both of which can be specifically blocked with NS1-immune polyclonal mouse sera or anti-NS1 mAbs. These results suggest that NS1 can cause endothelial dysfunction leading to vascular leakage during severe dengue disease. In addition, we demonstrated that immune responses elicited by vaccination with DENV2 NS1 protect against lethal challenge with high-dose or antibody-enhanced DENV2 infection, comparable to immunization with a primary sublethal DENV2 infection. Furthermore, vaccination with DENV1, DENV3, or DENV4 NS1 provided substantial protection against a heterologous DENV2 lethal challenge. Our findings, along with those in the accompanying paper by Modhiran et al. (32), add an important and previously overlooked component to the induction of vascular leak in severe dengue.

NS1 levels have been shown to correlate with disease severity (11, 28), and although NS1 antigenemia peaks concurrently with viremia early in disease, cumulative effects of NS1 on the endothelium might occur after several days of antigenemia, during the “critical phase” on days 4 to 6 post-symptom onset when hypovolemic shock is observed. This would be consistent with our finding that mice displayed the greatest vascular leak and morbidity 3 days after injection with NS1 alone and experienced the most severe disease 3 days after inoculation with NS1 combined with a sublethal dose of DENV. We found evidence of vascular leak in the lung, liver, spleen, and lymph nodes of mice, which parallels the finding that most of the histopathological damage identified in fatal human cases of dengue disease occurs in these tissues as well (33, 34). In terms of the physiological relevance of our findings, the in vitro and in vivo effects of NS1 occurred at concentrations similar to those reported in patients with DHF/DSS (27, 28). We also observed a correlation between the amount of circulating NS1, the degree of vascular leak, and production of inflammatory cytokines (IL-6 and TNF-α) in vivo. This is consistent with NS1 triggering increased production of vasoactive cytokines by monocytes and macrophages, as shown in the accompanying paper (32). Finally, we studied the effects of NS1 on human endothelial cell monolayers (HPMECs and HUVECs) and demonstrated that DENV, but not WNV, NS1 can disrupt endothelial cell permeability in a dose- and time-dependent manner. These in vitro results indicate that NS1 can act directly on the endothelial barrier to increase vascular permeability. These findings are consistent with those of Modhiran et al. (32), which showed that NS1 triggers endothelial permeability directly in human dermal microvascular endothelial cells within several hours of addition. Several possible mechanisms could explain the direct contribution of NS1 to vascular leak, including disruption of components of the endothelial glycocalyx layer and extracellular matrix and mislocalization or degradation of intercellular-junction proteins triggered by activation of intracellular signaling pathways (35, 36).

We show here that vaccination with NS1 protects against homologous and heterologous lethal challenge in Ifnar−/− mice, currently the in vivo model that best mimics features of severe human dengue (30). Previous studies using intracranial challenge demonstrated that immunization with DENV2 NS1 protected against homologous but not heterologous DENV serotypes (18). Earlier work also demonstrated that the passive transfer of NS1-specific mouse polyclonal antibodies or mAbs protected against intracranial homologous challenge with DENV2 (20, 21). More recent work has shown that an NS1 DNA vaccine as well as NS1 combined with a heat-labile toxin adjuvant can protect against intracranial challenge (23, 25, 26) in BALB/c mice. Our data show that vaccination with NS1 protects against lethal DENV–induced vascular leakage syndrome in mice and that anti–NS1-immune sera or anti-NS1 mAbs can prevent NS1-mediated vascular leakage both in vivo and in vitro. The antibody-derived immunity to NS1 could be mediated via an Fc-dependent pathway, complement-dependent pathways (37), or inhibition of the pathogenic effects of NS1. We suggest that antibodies to NS1 generated from vaccination can increase virus clearance as well as neutralize the vasoactive effects of NS1. Together, our data indicate that immunization with NS1 could provide critical protection against severe DENV disease without the risk of ADE and argue for the inclusion of DENV NS1 in dengue vaccines.

Although anti-NS1 antibodies can have a potential pathogenic effect because of cross-reactivity with human endothelial cells, platelets, or thrombin (15–17), we observed a protective rather than a pathogenic effect of anti-NS1 polyclonal antibodies or mAbs on endothelial cells. Heat-inactivated anti-NS1 sera lacking active complement components blocked NS1-mediated endothelial permeability, as did anti-NS1 mAbs added to HPMECs in the absence of complement. Our results demonstrate that DENV NS1 has a direct effect on endothelial cells and suggest that NS1 triggers vascular leakage in the absence of antibodies or complement. Finally, although antibodies to NS1 are reported more frequently after secondary DENV infection (38), it is possible that the repertoire of anti-NS1 antibodies and the amount of free NS1 (27, 28) may differ in patients who develop severe as compared to mild disease, a topic of future investigation.

In addition, we found that exogenous NS1 resulted in increased viral burden in vivo, which may also exacerbate disease. This is consistent with data showing increased viral output in DENV-infected cells exposed to exogenous NS1 (39). It also could result from the ability of NS1 to antagonize activation of complement pathways (8, 13), which can directly neutralize DENV in plasma (13, 14, 40) and control virus replication in vivo. We also noted that mice receiving a lethal dose of DENV2 alone displayed high levels of vascular leakage and inflammatory cytokines with only a partial increase in circulating NS1. This suggests that the increase in vascular leakage leading to mortality in the high-dose infection with DENV2 is partially attributable to virus-induced damage in addition to the pathogenic effects of NS1. This is consistent with a report by Watanabe et al. (41), which demonstrated differences among DENV2 strains in relation to mortality that were independent of the NS1 levels in a mouse model of DENV infection. It is also possible that strain-related differences in NS1 can modulate the pathogenic properties of NS1.

One of the limitations of this study was our ability to explore different kinetics of NS1 delivery in vivo. We delivered the NS1 in vivo in a single dose, which resulted in circulating levels initially 15 μg/ml at 12 h (on the high end of what has been seen in humans) that decrease to ~1 μg/ml at 72 h (more often the range seen in severe dengue cases); the rapid decline in NS1 levels may be attributable to protein degradation or clearance from the bloodstream. However, another paper that examined levels of NS1 in a mouse model of DENV2 infection reported circulating levels of NS1 in mice of 8 to 30 μg/ml (41). It will be interesting to explore different kinetics of delivery of NS1 in vivo. This study was also limited by our ability to differentiate, in the mouse model, between NS1 triggering endothelial permeability directly versus NS1 triggering mediators that may be acting on endothelial cells. Evaluating the precise role of signaling molecules and inflammatory mediators, including cytokines, in the mechanisms of NS1-induced vascular leak in vivo requires study in genetically deficient mice and the use of various inhibitors and/or antibodies; these studies are currently underway. In separate in vitro experiments, we have identified cytokine-independent, endothelial cell–intrinsic mechanisms through which NS1 leads to increased endothelial permeability, in addition to the cytokine-dependent pathways triggered by NS1 described by Modhiran et al. (32).

To date, the dominant theory to explain dengue shock invokes immunopathogenic processes thought to lead to endothelial dysfunction; here, we propose that DENV NS1 protein by itself is a key component in triggering the severe vascular leakage associated with life-threatening dengue. This work opens the door to evaluating potential drug therapeutics that can inhibit NS1-mediated disease. Likewise, our NS1 vaccination data showing protection against DENV lethal vascular leak syndrome points to the importance of including NS1 in dengue vaccine formulations.


We designed these studies to show that DENV NS1 plays a role in causing vascular leakage and that immunization with NS1 could prevent DENV-induced systemic disease. We first showed that recombinant NS1 as a vaccine could protect against lethal DENV–induced vascular leak syndrome and then followed this with studies of NS1 alone or NS1 combined with a sublethal DENV infection to characterize disease due to increased levels of NS1. Mice infected with DENV with and without NS1 were evaluated on a morbidity scale from 1 to 5 (30). Mice were monitored every 12 h after infection, followed every 6 h when displaying a score of >3, and euthanized immediately when they became moribund (score of 5). NS1 immunization experiments included negative controls consisting of OVA-immunized or unimmunized mice that were not protected and DENV2 PL046-immunized mice as positive controls that were protected against lethal challenge. In NS1 vascular leak experiments, OVA-injected mice were used as negative controls in comparison to NS1-injected mice, and sublethal DENV infection plus OVA was included as a negative control compared to sublethal DENV infection plus NS1. Mouse experiments testing mortality or protection from lethal DENV challenge had endpoints 10 days after infection, and no NS1-immunized, NS1-injected, or DENV-infected mice were excluded from the study. Mouse experiments were performed in duplicate, with numbers totaling four or greater in each group. We then hypothesized that DENV NS1 directly induces endothelial permeability and used in vitro TEER experiments with cultured human endothelial cell lines to evaluate this effect. Each TEER experiment was performed two to three times, with each condition including two replicate wells that were each read twice. Each experiment contained the following controls: (i) Transwell inserts containing only medium to determine transient resistance values of the permeable membrane, (ii) Transwell inserts with cultured human endothelial cells to obtain resistance values of the endothelial cell monolayer alone, and (iii) a positive control consisting of vasoactive molecules such as TNF-α, which is known to increase endothelial permeability. In addition, as an irrelevant protein control, OVA was included in each experiment. For the protection experiments using sera obtained from NS1-vaccinated mice or anti-NS1 mAbs, Transwells containing only sera or anti-NS1 mAbs were included to exclude any effect on endothelial permeability induced by these components. TEER values were collected every 2 h for 12 h and at 24 h, then the medium was replaced to reestablish the integrity of the monolayer, and the TEER values were read at 26 and 48 h. No blinding or randomization was performed for either the mouse studies or the TEER experiments.


Six- to eight-week old Ifnar−/− C57BL/6 mice were bred and maintained under specific pathogen–free conditions at the University of California, Berkeley, Animal Facility. Experiments were performed strictly following guidelines of the American Veterinary Medical Association and the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Animal Care and Use Committee of the University of California, Berkeley, approved all experiments (protocol R252-1012B).

Cell cultures and viruses

All viruses were propagated in the Aedes albopictus C6/36 cell line [American Type Culture Collection (ATCC)] and titered by plaque assay on baby hamster kidney cells (BHK21, clone 15). DENV2 PL046 was obtained originally from H.-Y. Lei (National Cheng Kung University, Taiwan). DENV2 D220 was produced in our laboratory from the parental strain DENV2 PL046 (42). An HPMEC line (HPMEC.ST1.6R) was donated by J. C. Kirkpatrick (Institute of Pathology, Johannes Gutenberg University, Germany), propagated (passages 5 to 8), and maintained at 37°C in humidified air with 5% CO2 in endothelial cell basal medium-2 supplemented with growth factors, antibiotics, and fetal bovine serum as per the manufacturer’s specifications (Clonetics, Lonza). HUVECs (passage 3) were donated by M. Lodoen (University of California, Irvine) and maintained as described above.

Recombinant NS1 proteins and anti-NS1 mAbs

Recombinant NS1 proteins from DENV1, DENV2, DENV3, and DENV4 and WNV, greater than 95% purity and certified to be free of endotoxin contaminants, were produced by Native Antigen in HEK 293 cells; recombinant DENV2 NS1 produced in S2 cells was obtained from Merck. The recombinant DENV2 envelope (recE), expressed in a baculovirus expression vector system (GenScript) using High Five insect cells, was purified by an immune-affinity protein G column coupled to 4G2 (anti-E mAb). The NS1 and recE working stocks were also tested using the Endpoint Chromogenic Limulus Amebocyte Lysate (LAL) QCL-1000TM kit (Lonza) and confirmed to be bacterial endotoxin-free (<0.1 EU/ml per 25 μg of protein). Anti-NS1 mAbs were obtained as follows: 2B7 and 2E9.E2 were generated in the Harris laboratory (P.R.B. and E.H., unpublished), and 1H7.4 was a gift from P. Young (University of Queensland, Brisbane, Australia). mAb 3H5 (anti-DENV2 E) was obtained from ATCC. Hybridomas were propagated in CELLine culture flasks (Sigma); supernatants were collected, and the mAbs were affinity-purified using a Protein G Sepharose column. The mAbs were eluted from the column, concentrated, sterile-filtered, and titered before use.

Mouse experiments of NS1-induced vascular leak and NS1 vaccination

For studies of NS1-induced vascular leak, Ifnar−/− mice were injected intravenously with NS1 (5 to 20 μg/kg) or OVA protein (10 μg/kg) alone or NS1 (5 to 10 μg/kg) or OVA (10 μg/kg) in combination with a sublethal dose of 106 PFU of DENV2 D220. Separate groups of mice were administered 106 PFU of DENV2 D220 alone as a sublethal control or 107 PFU of DENV2 D220 as a lethal control. Mice were observed every 12 h for morbidity using a scoring system on a scale of 1 to 5 as follows: 1 = healthy; 2 = ruffled fur and mild signs of lethargy; 3 = hunched posture, ruffled fur, and intermediate level of lethargy and failure to groom; 4 = very lethargic, limited mobility, ruffled fur, and hunched posture; and 5 = moribund with limited to no mobility and inability to reach food or water. Mice were euthanized immediately when they became moribund. For vascular leak studies and measurement of cytokines and levels of sNS1 and viral RNA, mice were euthanized 72 h after injection, blood was collected via cardiac puncture, and tissues were harvested. For mortality studies, mice were monitored for 10 days after injection. For vaccination studies, Ifnar−/− mice were injected intraperitoneally three times (days 0, 14, and 42) with 20 μg of NS1 or 20 μg of OVA with 1 μg of MPLA (InvivoGen) and AddaVax (0.5% sorbitan trioleate, 5% squalene, and 0.5% Tween 80 in 10 mM sodium citrate buffer; InvivoGen). Two weeks after the third immunization (day 56), mice were challenged with 107 PFU of DENV2 D220 intravenously or 5 μg of 4G2 (anti-E mAb) 24 h before 105 PFU of D220 (ADE). To test the effects of the anti–NS1-immune serum on NS1-induced vascular leak, Ifnar−/− mice were injected with 10 μg of NS1 or 10 μg of OVA in combination with 106 PFU of DENV2 D220, immediately administered 300 μl of polyclonal anti-NS1, anti-OVA, or anti–PL046-immune serum intraperitoneally, and then followed for morbidity and mortality for 10 days. The immune serum used for passive transfer was collected from NS1- or OVA-immunized mice or DENV PL046–infected mice 6 weeks after initial immunization or infection. To test the effects of anti-NS1 mAb on NS1-induced vascular leak, Ifnar−/− mice were injected with 10 μg of NS1 or 10 μg of OVA in combination with 106 PFU of DENV2 D220, immediately given 200 μg of anti-NS1 mAb (1H7.4) or isotype control antibody intraperitoneally, and then followed for morbidity and mortality for 10 days. Separate groups of mice were given 106 PFU of DENV2 D220 alone as a sublethal control or 107 PFU of DENV2 D220 as a lethal control.

Enzyme-linked immunosorbent assays

Serum was collected 3 days after the intravenous injection of NS1 with or without DENV infection. Serum was analyzed by NS1-specific capture ELISA using mAb 7E11 (5 μg/ml; a gift from R. Putnak, Walter Reed Army Institute of Research) as a coating antibody, 50 μl of a 1:100 dilution of each mouse serum sample, followed by detection using 100 μl of a biotinylated NS1-specific mAb, 2B7 (4 μg/ml) (P.R.B. and E.H., unpublished). A standard curve of NS1 (7 to 2000 ng/ml) was run in parallel to quantify NS1 concentration in all samples. Absorbance [optical density at 405 nm (OD405)] was measured using an Applied Biosystems 7200 microplate reader. To determine levels of NS1-specific antibodies in immunized mice before challenge, serum was obtained 1 week after the third immunization via submandibular bleed. For the ELISA, 50 μl of NS1 (0.5 μg/ml) was coated onto a Nunc Immulon polystyrene plate; after blocking with 5% nonfat dry milk in phosphate-buffered saline (PBS) + 0.05% Tween 20 (PBS-T), 50 μl of a 1:100 dilution of each test serum was added and incubated for 24 h. After washing with PBS-T, biotinylated goat anti-mouse immunoglobulin G (Jackson ImmunoResearch) was added, followed by washing and addition of streptavidin–alkaline phosphatase (Life Technologies) and para-Nitrophenylphosphate (Sigma-Aldrich) substrate, which was read at OD405 as above. Capture ELISAs were performed to quantitate the levels of TNF-α or IL-6 in citrated plasma. Mouse TNF-α and IL-6 ELISA Ready-SET-Go! kits (eBioscience) were used according to the manufacturer’s instructions. The OD405 of each sample was measured, and cytokine levels in serum were expressed in picograms per milliliter.

Quantitation of virus by qRT-PCR

Samples of all tissues were stored in RNA later (Ambion), and RNA was extracted using an RNeasy Mini kit (Qiagen). Serum was generated from whole blood by centrifugation, and RNA was extracted using a QIAamp Viral Recovery RNA kit (Qiagen). Serum viremia levels and tissue viral load were measured by qRT-PCR as described previously (29). Viral load was expressed as either glyceraldehyde phosphate dehydrogenase in genome equivalents per microgram (tissue) or genome equivalents per millilter (serum).

Quantitation of Evans blue vascular leakage

Vascular leakage was quantified by Evans blue dye as previously described (42). Briefly, 200 μl of 0.5% Evans blue dye was injected intravenously 3 days after treatment and allowed to circulate for 1 h before mice were euthanized and cardiac puncture was performed. Tissues were collected in preweighed tubes containing 1 ml of formamide and incubated at 37°C and 5% CO2 for 24 h. Evans blue concentration in extracts was quantified by measuring OD610 in samples and comparing to a standard curve. Data were expressed as nanograms of Evans blue dye per milligram of tissue weight.

Transendothelial electrical resistance

To evaluate the effect of sNS1 on the integrity of the endothelium, HPMEC or HUVEC monolayers grown on a 24-well Transwell polycarbonate membrane system (Transwell permeable support, 0.4 μM, 6.5-mm insert; Corning Inc.) were incubated with NS1 (0.2 to 20 μg/ml) or OVA (1 to 20 μg/ml) as a negative control. Endothelial permeability was evaluated by measuring TEER in ohms at sequential 2-h time points after the addition of test proteins. TEER was measured using an epithelial voltohmmeter with “chopstick” electrodes (World Precision Instruments). Transwell inserts containing untreated HPMEC cells were used as a negative control, and inserts with medium alone were used for blank resistance measurements. Relative TEER was expressed as the ratio of resistance value as follows: [ohm (experimental condition) − ohm (medium alone)]/[ohm (nontreated endothelial cells) − ohm (medium alone)]. After 24 h of treatment, 50% of upper and lower chamber media was replaced by fresh endothelial cell medium.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 6 software, and all graphs were generated using Prism 6. Comparison between ELISA and qRT-PCR titers was conducted using a nonparametric Mann-Whitney test. Comparison of survival rates was conducted using a nonparametric log-rank (Mantel-Cox) test and graphed as Kaplan-Meier survival curves. For TEER experiments, statistical significance was determined using a two-way analysis of variance (ANOVA), and differences in treatment were considered significant for P values <0.05.


Fig. S1. Recombinant NS1 from DENV1, DENV2, DENV3, DENV4, and WNV is highly purified and oligomeric.

Fig. S2. Morbidity and vascular leakage are induced by NS1.

Fig. S3. NS1 increases endothelial cell permeability in two different endothelial cell lines, HUVEC and HPMEC.

Fig. S4. Viremia after lethal DENV challenge is reduced by immunization with DENV2 NS1.

Fig. S5. Immunization with DENV NS1 and DENV infection induces serotype cross-reactive anti-NS1 antibodies.

  • Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control (World Health Organization, Geneva, ed. 2, 1997), pp. 12–23.

  • Acknowledgments: We thank S. Zompi, S. Orozco, and S. Balsitis for early contribution to the project; M. Diamond, S. Halstead, J. Coloma, and A. Green for helpful discussions and advice; M. Schmid and M. Diamond for useful comments on the manuscript; B.-A. Coller for scientific discussion and enabling purchase of NS1; A. Azliyati for facilitating transfer of HPMECs; P. Young for the mAb 1H7.4; and G. Firestone for loaning necessary equipment. Funding: This work was supported by grant U54 AI65359 (E.H.) from the U.S. National Institute of Allergy and Infectious Diseases. Author contributions: P.R.B., H.P.-G., and E.H. conceived and designed the experiments. S.S.K. and K.H. performed the in vivo experiments and ELISAs; H.P.-G. and D.R.G. performed the TEER experiments, Western blots, and silver-stained gels. P.R.B., H.P.-G., S.S.K., D.R.G., K.H., and E.H. analyzed the data. P.R.B., H.P.-G., S.S.K., D.R.G., and E.H. wrote the paper. Competing interests: The authors declare that they have no competing financial interests. Data and materials availability: Anti-NS1 mAbs are available upon request.

  • Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis | real questions and Pass4sure dumps

    Interventions To Prevent Retinopathy of Prematurity: A Meta-analysis | Review Articles | Pediatrics

    '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //-->

    Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE | real questions and Pass4sure dumps


    All experimental protocols were approved by the Research Ethics Committee of the Nanjing Medical University. All experiments were conducted in compliance with the guidelines for the care and use of laboratory animals and approved by Institutional Animal Care and Use Committee of Nanjing Medical University. The normal diet was from Xietong Biotechnology Co.Ltd (Jiangsu, China). The fish oil was from ShangHai HOPE industry Co. Ltd (Shanghai, China). The high ω-3 PUFAs diet was made by the normal diet mixed with 5% Fish-Oil (FO). The animals were fed food and water ad libitum, housed at 22 °C and a 12-h light-dark cycle.


    All cell culture reagents were purchased from Gibco BRL Technology. AA, EPA, DHA, propidium iodide (PI), and PUFA analytical standards were obtained from Sigma-Aldrich (St. Louis, MO, USA). Water-soluble tetrazolium (WST) reagent was from Dojindo Laboratories (Kumamoto, Japan). The following were commercially obtained antibodies: PTEN antibody, Ki-67 antibody, Cyclin D1 antibody, anti-phospho-Akt antibody (Ser473), Akt antibody (Cell Signaling Technology Danvers, MA, USA); anti-β-actin antibody (Abcam, Cambridge, UK); anti- COX-2 antibody and PGE2 (Cayman Chemical Co, Ann Arbor, MI, USA)

    Generation of mice with mfat-1;PTEN+/−

    The PTENloxP/loxP mice21 and zona pellucida 3 (Zp3)-Cre transgenic mice were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China). The mfat-1 transgenic mice were described in our previous studies20. All above strains of mice have a C57BL/6J genetic background. The PTEN gene was deleted specifically from oocytes of primary follicles by crossing Zp3-Cre mice with PTENloxP/loxP mice as previously described53. The female offspring was crossed with male mfat-1 transgenic mice to generate four different genotypes for experiments (PTEN+/+, mfat-1, PTEN+/−, mfat-1;PTEN+/−). The PTEN+/+ and mfat-1 mice were served as littermate control.

    The uterus sections from the female mice at 26 weeks of age were subjected to histopathological analyses. Normal (N): the endometrium is covered with columnar lining epithelium with widely separated tubular glands embedded in a cellular stroma; Simple hyperplasia (SH): increased number of simple tubular glands or the glands covered by crowded hyperplastic epithelium; Complex atypical hyperplasia (CAH): enlarged and irregularly branching endometrial glands; Carcinoma (CA): glands with multilayer cells and extensive cribriform structures or sheets of large pleomorphic epithelial cells.

    PCR Analysis of PTEN and mfat-1 Genotypes

    Tail genomic DNA samples were isolated and amplified by PCR following by a previously described protocol20. Sense primer (5′-CTCCTCTACTCCATTCTTCCC-3′) and anti-sense primer (5′-ACTCCCACCAATGAACAAAC-3′) were used to detect the PTENloxp/loxp allele, sense primer (5′-GTCACCAGGATGCTTCTGAC-3′) and anti-sense primer (5′-TGGCAAGCTTTCAACTTGTTT-3′) were used to detect PTEN+/−, sense primer (5′-GGACCTGGTGAAGAGCATCCG-3′) and anti-sense primer (5′-GCCGTCGCAGAAGCCAAAC-3′) were used to detect the mfat-1, and sense primer (5′-CAGATGAGGTTTGAGGCCACAG-3′) and anti-sense primer (5′-CAGGTGTTATAAGCAATCCC-3′) were used to detect Zp3-Cre transgene. Amplified fragments of 325 bp, 750 bp, 438 bp, and ~500 bp were obtained, respectively.

    Tumor xenograft models

    Four-week-old female BALB/c nude mice were injected with 5 × 106/0.1 ml of RL95-2 cells into the flanks. The mice were randomized into three groups (n = 10). Group 1 was implanted with RL95-2-GFP cells and fed with normal diet. Group 2 was implanted with RL95-2-GFP cells and fed with high ω-3 PUFAs diet (normal diet mixed with 5% FO). Group 3 was implanted with RL95-2-mfat-1 cells and fed with normal diet. Bi-dimensional tumor measurements were taken every two days. Tumor volume was measured along two major axes using calipers. Tumor volume (mm3) was calculated as follows: V = 1/2 LW2 (L: length, W: width).

    Cell culture and proliferation assays

    The endometrial cancer cell lines RL95-2 was obtained from American Type Culture Collection (ATCC). RL95-2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 5% fetal calf serum, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 °C with 5% CO2. Cell proliferation assays were performed in 96-well plate. PUFAs were added with serial concentrations (20–100 μM) for 24 h. Then cells were stained with WST at 37 °C for 1 h and quantified by the absorbance at 450 nm.

    Overexpression of mfat-1 by lentiviral transfection

    The description of mfat-1 cDNA has been described previously20. The mfat-1 cDNA was synthesized and cloned into the PLJM1 lentivirus vector (Addgene, Palo Alto, CA, USA). To produce the virus, pMD2.G and psPAX2 were co-transfected with PLJM1-mfat-1 or the vehicle plasmid into 293T cells using X-tremeGENE HP DNA transfection reagent, according to manufacturer’s instructions. To obtain a stable mfat-1 overexpressing cell line, lentivirus-containing supernatant was harvested 48 hours after transfection and used to infect RL95-2 cells.

    Quantitative analysis of gene expression levels in cells and tissues

    Total RNA was prepared using TRIZOL reagent, treated with DNase I, and reverse transcribed with a Superscript kit. Real-time PCR assay was carried out on an Applied Biosystems StepOnePlus™ Systems with the following cycles: 50 °C for 2 min, one cycle; 95 °C for 30 s, one cycle; and 95 °C for 15 s, 58 °C for 30 s and 72 °C for 30 s, 40 cycles.

    Western blotting

    Cells were treated with various PUFA or PGE2 agents at 37 °C for various times, as indicated in the experiments. The cells were collected and subjected to Western blotting analysis. The immunoreactivity was detected by using a standard enhanced-chemiluminescent reaction and analyzed using Image Lab 4.0 analysis software from Bio-Rad.

    Immunohistochemical staining

    The tissue specimens were incubated with antibodies against phospho-Akt, Ki-67, Cyclin D1, and COX-2. The specific signals were detected using EnVision polymer technology, and visualization was performed with 3, 3N-diaminobenzidine tetrahydrochloride (DAB). The sections were photographed by Nikon microscopy and image analyses system. The expression levels of proteins were quantitated using Image Pro Plus 6.0 software (Media Cybernetics Inc., New York, USA).

    Analysis of cell cycle

    After RL95-2 cells were incubated in serum-free medium overnight, cells were collected and rinsed with PBS twice. For cell cycle analysis, the cells were fixed in 70% pre-cold ethanol at 4 °C overnight and stained by PI. The DNA content was analyzed using a BD FACStar flow cytometer.

    Gas chromatography analysis of fatty acid compositions

    Lipids extraction from cells and tissues were performed according to a previous report41. The gas chromatography was done on an Agilent 7890A. Identification of components was done by comparison of retention times with those of PUFA analytical standard.

    Systematic metabolomic analysis of eicosanoids

    The RL95-2 cells were seeded in 15 cm dish 24 hours before adding various PUFA. After digesting with 0.25% trypsin, cells were washed twice by PBS and counted. 2 × 107 cells were needed for eicosanoid analysis in each sample. Eicosanoid extraction was performed according to a previous report54. Chromatographic separation involved an ACQUITY UPLC BEH C18 column consisting of ethylene-bridged hybrid particles. The metabolites were quantified by use of a 5500 QTRAP hybrid triple quadrupole linear ion trap mass spectrometer equipped with a Turbo Ion Spray electrospray ionization (ESI) source.

    Statistical analysis

    Data are presented as mean ± SD of at least three independent experiments. Differences between groups were analyzed using Student’s t test or one-way ANOVA, and a level of P < 0.05 was considered statistically significant.

    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]

    References :

    Dropmark :
    Wordpress :
    Dropmark-Text :
    Blogspot :
    RSS Feed : :

    Back to Main Page

    Symantec 250-510 Exam (Administration of SymantecTM Data Loss(R) Prevention 10.5 - BETA) Detailed Information


    Pass4sure Certification Exam Study Notes-
    Download Hottest Pass4sure Certification Exams - CSCPK
    Complete Pass4Sure Collection of Exams - BDlisting
    Latest Exam Questions and Answers -
    Pass your exam at first attempt with Pass4Sure Questions and Answers -
    Here you will find Real Exam Questions and Answers of every exam -
    Hottest Pass4sure Exam at
    Download Hottest Pass4sure Exam at ada.esy
    Pass4sure Exam Download from
    Pass4sure Exam Download from airesturismo
    Practice questions and Cheat Sheets for Certification Exams at linuselfberg
    Study Guides, Practice questions and Cheat Sheets for Certification Exams at brondby
    Study Guides, Study Tools and Cheat Sheets for Certification Exams at
    Study Guides, Study Tools and Cheat Sheets for Certification Exams at brainsandgames
    Study notes to cover complete exam syllabus - crazycatladies
    Study notes, boot camp and real exam Q&A to cover complete exam syllabus -
    Study notes to cover complete exam syllabus - carspecwall
    Study Guides, Practice Exams, Questions and Answers - cederfeldt
    Study Guides, Practice Exams, Questions and Answers - chewtoysforpets
    Study Guides, Practice Exams, Questions and Answers - Cogo
    Study Guides, Practice Exams, Questions and Answers - cozashop
    Study Guides, Study Notes, Practice Test, Questions and Answers - cscentral
    Study Notes, Practice Test, Questions and Answers - diamondlabeling
    Syllabus, Study Notes, Practice Test, Questions and Answers - diamondfp
    Updated Syllabus, Study Notes, Practice Test, Questions and Answers -
    New Syllabus, Study Notes, Practice Test, Questions and Answers -
    Syllabus, Study Notes, Practice Test, Questions and Answers -
    Study Guides, Practice Exams, Questions and Answers - Gimlab
    Latest Study Guides, Practice Exams, Real Questions and Answers - GisPakistan
    Latest Study Guides, Practice Exams, Real Questions and Answers - Health.medicbob
    Killexams Certification Training, Q&A, Dumps -
    Killexams Syllabus, Killexams Study Notes, Killexams Practice Test, Questions and Answers -
    Pass4sure Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Pass4sure Brain Dump, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers - levantoupoeira
    Pass4sure Braindumps, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Pass4sure Braindumps, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Pass4sure study guides, Braindumps, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers - (c) 2017